Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28000694 | 0.97 | DUT (0.33) | DUT | |
| SCHEMBL94712 | 0.85 | DUT (0.39) | DUT | |
| SCHEMBL97324 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL11580466 | 0.83 | DUT (0.42) | DUT | |
| SCHEMBL97731 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL9517441 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL9517422 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL7674744 | 0.78 | DUT (0.41) | DUT | |
| SCHEMBL8063404 | 0.78 | DUT (0.43) | DUT | |
| SCHEMBL132024 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384079-B | Chiral N-alkyl indole compound and preparation method and application thereof | 云南大学 | 2024-05-24 | — | — | CN | claimed |
| CN-117384079-A | Chiral N-alkyl indole compound and preparation method and application thereof | 云南大学 | 2024-01-12 | — | — | CN | claimed |
| CN-115536704-A | Nitrogen bismuth octa-cycloalkyl bismuth compounds and synthesis method thereof | 湖南大学 | 2022-12-30 | — | — | CN | claimed |
| CN-115093448-A | Nitrogen-antimony octylene alkyl antimony derivatives and synthesis method thereof | 湖南大学 | 2022-09-23 | — | — | CN | claimed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| WO-1996040692-A1 | ORGANOLITHIUM PROCESS | FMC CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | claimed |
| US-5359073-A | Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists | G. D. SEARLE & CO. (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | claimed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | claimed |
| CN-117384079-B | Chiral N-alkyl indole compound and preparation method and application thereof | 云南大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-113227174-B | Functionalized rubbers | 戴纳索尔埃拉斯托默罗斯有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117384079-A | Chiral N-alkyl indole compound and preparation method and application thereof | 云南大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-115260064-B | Alkenyl thioether prepared by terminal alkyne high cis-form selective hydrosulfide and synthetic method thereof | 湖南大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116848113-A | Bicyclic compounds as HPK1 inhibitors and application thereof | 南京再明医药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-1997045429-A1 | BETA-LACTAMS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997023520-A1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORPORATION (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1996040692-A1 | ORGANOLITHIUM PROCESS | FMC CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | DUT 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.